|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: BANF1 |
Gene summary for BANF1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | BANF1 | Gene ID | 8815 |
| Gene name | BAF nuclear assembly factor 1 | |
| Gene Alias | BAF | |
| Cytomap | 11q13.1 | |
| Gene Type | protein-coding | GO ID | GO:0006323 | UniProtAcc | A0A024R5H0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8815 | BANF1 | P47T-E | Human | Esophagus | ESCC | 6.85e-51 | 1.36e+00 | 0.1067 |
| 8815 | BANF1 | P48T-E | Human | Esophagus | ESCC | 1.10e-51 | 1.19e+00 | 0.0959 |
| 8815 | BANF1 | P49T-E | Human | Esophagus | ESCC | 8.47e-26 | 3.90e+00 | 0.1768 |
| 8815 | BANF1 | P52T-E | Human | Esophagus | ESCC | 2.38e-91 | 2.76e+00 | 0.1555 |
| 8815 | BANF1 | P54T-E | Human | Esophagus | ESCC | 6.22e-56 | 1.68e+00 | 0.0975 |
| 8815 | BANF1 | P56T-E | Human | Esophagus | ESCC | 2.01e-17 | 3.00e+00 | 0.1613 |
| 8815 | BANF1 | P57T-E | Human | Esophagus | ESCC | 1.84e-52 | 1.46e+00 | 0.0926 |
| 8815 | BANF1 | P61T-E | Human | Esophagus | ESCC | 1.27e-35 | 1.66e+00 | 0.099 |
| 8815 | BANF1 | P62T-E | Human | Esophagus | ESCC | 5.55e-109 | 2.35e+00 | 0.1302 |
| 8815 | BANF1 | P65T-E | Human | Esophagus | ESCC | 1.05e-76 | 1.94e+00 | 0.0978 |
| 8815 | BANF1 | P74T-E | Human | Esophagus | ESCC | 3.62e-72 | 3.23e+00 | 0.1479 |
| 8815 | BANF1 | P75T-E | Human | Esophagus | ESCC | 1.69e-116 | 2.96e+00 | 0.1125 |
| 8815 | BANF1 | P76T-E | Human | Esophagus | ESCC | 2.08e-99 | 2.58e+00 | 0.1207 |
| 8815 | BANF1 | P79T-E | Human | Esophagus | ESCC | 3.93e-85 | 2.20e+00 | 0.1154 |
| 8815 | BANF1 | P80T-E | Human | Esophagus | ESCC | 3.39e-64 | 2.61e+00 | 0.155 |
| 8815 | BANF1 | P82T-E | Human | Esophagus | ESCC | 2.01e-32 | 2.42e+00 | 0.1072 |
| 8815 | BANF1 | P83T-E | Human | Esophagus | ESCC | 6.91e-75 | 3.07e+00 | 0.1738 |
| 8815 | BANF1 | P84T-E | Human | Esophagus | ESCC | 8.04e-16 | 1.62e+00 | 0.0933 |
| 8815 | BANF1 | P89T-E | Human | Esophagus | ESCC | 3.82e-35 | 3.72e+00 | 0.1752 |
| 8815 | BANF1 | P91T-E | Human | Esophagus | ESCC | 1.16e-26 | 4.19e+00 | 0.1828 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001603210 | Cervix | CC | viral process | 109/2311 | 415/18723 | 5.40e-15 | 6.46e-12 | 109 |
| GO:001905810 | Cervix | CC | viral life cycle | 87/2311 | 317/18723 | 2.20e-13 | 1.20e-10 | 87 |
| GO:001907910 | Cervix | CC | viral genome replication | 35/2311 | 131/18723 | 6.11e-06 | 1.49e-04 | 35 |
| GO:00096158 | Cervix | CC | response to virus | 73/2311 | 367/18723 | 2.22e-05 | 3.95e-04 | 73 |
| GO:005079210 | Cervix | CC | regulation of viral process | 38/2311 | 164/18723 | 8.12e-05 | 1.10e-03 | 38 |
| GO:190390010 | Cervix | CC | regulation of viral life cycle | 33/2311 | 148/18723 | 4.86e-04 | 4.76e-03 | 33 |
| GO:00485256 | Cervix | CC | negative regulation of viral process | 23/2311 | 92/18723 | 6.39e-04 | 5.97e-03 | 23 |
| GO:00450698 | Cervix | CC | regulation of viral genome replication | 21/2311 | 85/18723 | 1.27e-03 | 1.01e-02 | 21 |
| GO:00450714 | Cervix | CC | negative regulation of viral genome replication | 15/2311 | 56/18723 | 2.60e-03 | 1.80e-02 | 15 |
| GO:0016032 | Colorectum | AD | viral process | 168/3918 | 415/18723 | 4.67e-20 | 3.66e-17 | 168 |
| GO:0019058 | Colorectum | AD | viral life cycle | 119/3918 | 317/18723 | 6.18e-12 | 8.23e-10 | 119 |
| GO:0019079 | Colorectum | AD | viral genome replication | 51/3918 | 131/18723 | 1.83e-06 | 5.51e-05 | 51 |
| GO:0050792 | Colorectum | AD | regulation of viral process | 59/3918 | 164/18723 | 5.95e-06 | 1.52e-04 | 59 |
| GO:1903900 | Colorectum | AD | regulation of viral life cycle | 51/3918 | 148/18723 | 9.01e-05 | 1.38e-03 | 51 |
| GO:0045069 | Colorectum | AD | regulation of viral genome replication | 32/3918 | 85/18723 | 2.97e-04 | 3.60e-03 | 32 |
| GO:00160321 | Colorectum | SER | viral process | 118/2897 | 415/18723 | 8.36e-12 | 1.65e-09 | 118 |
| GO:00190581 | Colorectum | SER | viral life cycle | 87/2897 | 317/18723 | 2.82e-08 | 1.94e-06 | 87 |
| GO:00190791 | Colorectum | SER | viral genome replication | 37/2897 | 131/18723 | 1.36e-04 | 2.72e-03 | 37 |
| GO:00507921 | Colorectum | SER | regulation of viral process | 43/2897 | 164/18723 | 2.57e-04 | 4.31e-03 | 43 |
| GO:19039001 | Colorectum | SER | regulation of viral life cycle | 38/2897 | 148/18723 | 8.76e-04 | 1.06e-02 | 38 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| BANF1 | SNV | Missense_Mutation | novel | c.118N>C | p.Asp40His | p.D40H | O75531 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-E2-A1LH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| BANF1 | deletion | Frame_Shift_Del | novel | c.261delC | p.Phe88SerfsTer84 | p.F88Sfs*84 | O75531 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| BANF1 | SNV | Missense_Mutation | c.205N>A | p.Ala69Thr | p.A69T | O75531 | protein_coding | deleterious(0.01) | benign(0.382) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| BANF1 | SNV | Missense_Mutation | c.65N>A | p.Ser22Asn | p.S22N | O75531 | protein_coding | tolerated(0.3) | benign(0.001) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| BANF1 | SNV | Missense_Mutation | rs772391821 | c.235N>A | p.Gly79Arg | p.G79R | O75531 | protein_coding | tolerated(0.54) | benign(0.123) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| BANF1 | SNV | Missense_Mutation | c.256N>A | p.Asp86Asn | p.D86N | O75531 | protein_coding | tolerated(0.19) | benign(0.041) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| BANF1 | SNV | Missense_Mutation | novel | c.20N>G | p.His7Arg | p.H7R | O75531 | protein_coding | deleterious(0.03) | probably_damaging(0.95) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| BANF1 | SNV | Missense_Mutation | c.45G>T | p.Met15Ile | p.M15I | O75531 | protein_coding | tolerated(0.08) | probably_damaging(0.999) | TCGA-44-7669-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | alimta | PD | |
| BANF1 | SNV | Missense_Mutation | c.124N>A | p.Ala42Thr | p.A42T | O75531 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-BR-6452-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| BANF1 | SNV | Missense_Mutation | novel | c.32T>C | p.Val11Ala | p.V11A | O75531 | protein_coding | deleterious(0.01) | possibly_damaging(0.527) | TCGA-HF-7134-01 | Stomach | stomach adenocarcinoma | Male | Unknown | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |